Vaxess Technologies is a pioneering biotech company specializing in the development of silk-based patches for the delivery of vaccines and therapies. Operating in the healthcare and pharmaceutical markets, Vaxess aims to revolutionize the way treatments are administered by leveraging the unique properties of silk to create smart release therapies. These patches are designed to mimic infections without the associated side effects, stimulating a more powerful and durable immune response. The company serves a diverse range of clients, including healthcare providers, pharmaceutical companies, and global health organizations.

Vaxess's business model focuses on research and development, partnering with other organizations to bring innovative solutions to market. The company generates revenue through the sale of its patches and through strategic partnerships and collaborations. By offering a more efficacious flu vaccine and developing a shelf-stable, self-applied SARS-CoV-2 vaccine, Vaxess is positioned to make significant contributions to global health.

The core technology involves applying a patch to the skin, where silk tips dissolve at a precise rate, releasing the treatment at its most effective dose over time. This method eliminates the need for needles and allows for a quick, simple, and painless application process. The patches can deliver treatments over a period ranging from minutes to months, making them highly versatile and effective.

Keywords: biotech, silk-based patches, vaccines, therapies, immune response, healthcare, pharmaceutical, global health, sustained release, innovative solutions.